Immunic raises USD 200 million in private placement, with potential for up to USD 200 million more. Funds to support Phase 3 trials and transition to commercial-stage company.
An initial sum of $200 million has been received upfront, with the possibility of an additional $200 million in proceeds. This funding is anticipated to cover the costs associated with finalizing the Phase 3 ENSURE trials for relapsing multiple sclerosis, commencing the Phase 3 trial for primary progressive multiple sclerosis, and facilitating the transition into the next phase of the project.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments